KCNH2 and breast carcinoma: Inhibition of the channel EAG reduces the migration of breast cancer cells as well as acute myeloid leukemia cells, whereas inhibition of ERG1 reduces the migration of leukemia, melanoma, and thyroid tumor cells (30).